

Electronic Acknowledgement Receipt

EFS ID:	5580046
Application Number:	10559982
International Application Number:	
Confirmation Number:	6583
Title of Invention:	Methods for treatment of parkinson's disease
First Named Inventor/Applicant Name:	Fariello Ruggero
Customer Number:	37509
Filer:	Daniel M. Becker/Paula Hurley
Filer Authorized By:	Daniel M. Becker
Attorney Docket Number:	373987-011US (102895)
Receipt Date:	24-JUN-2009
Filing Date:	02-FEB-2006
Time Stamp:	16:01:32
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment Type	Deposit Account
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2321
Deposit Account	502778
Authorized User	

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:

Charge any Additional Fees required under 37 C.F.R. Section 1.21 (Miscellaneous fees and charges)

File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		IDS_3.pdf	578820	yes	11
			ce66048834d187f54429f8873f9019eac3342dcc		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Transmittal Letter		1	4	
	Information Disclosure Statement (IDS) Filed (SB/08)		5	11	
Warnings:					
Information:					
2	NPL Documents	Andringa_TCH346.pdf	7656602	no	13
			f0f1107942085069da046eeea30875beab39dff2		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
3	NPL Documents	BenedettiAnticonvulsant.pdf	670245	no	6
			086d300a35cd7773f1bb9ac2ed22f69eaba9395		
Warnings:					
Information:					
4	NPL Documents	Calne_Manganism.pdf	1889043	no	4
			335cc98f62c74b9cd0dc4132efbbc3572f62d847		
Warnings:					
Information:					
5	NPL Documents	Chaudhuri_International.pdf	5186140	no	8
			352556ce32cd0602d9dcb9a6c4b72fc46015e6e		
Warnings:					
Information:					
6	NPL Documents	Chaudhuri_Metric.pdf	7026112	no	11
			b580812a15566855ec32926c8d1d7f8bdfccdde		
Warnings:					
Information:					
7	NPL Documents	Cho_Model.pdf	1594615	no	4
			907083a9de0e4c76bfe07548bc7226252fdb1209		

Warnings:					
Information:					
8	NPL Documents	Olanow_CURRICULUM_VITAE.pdf	325321	no	103
			f9ac2d1badb345fd0d5c548977aef943634da954		
Warnings:					
Information:					
9	NPL Documents	Dubois_Movement.pdf	7631988	no	11
			52aec5cda99e087ed34c617764b1fa06f3292209		
Warnings:					
Information:					
10	NPL Documents	Emre_Clinical.pdf	14056640	no	19
			f6e8f66d92daf71482031ebb53c76661f930f55f		
Warnings:					
Information:					
11	NPL Documents	Fahn_Levodopa.pdf	4172282	no	11
			05610306c5e00f4bad0277248289e3a281cfcb41		
Warnings:					
Information:					
12	NPL Documents	Freeman_UseofPlacebo.pdf	2440921	no	5
			bde6aaf073e3eefe7a05b54b1a51f2af773e49b7		
Warnings:					
Information:					
13	NPL Documents	Freeman_Bilateral.pdf	4748141	no	11
			e70f9600545ee5b366ded62ae61cac689c6b3885		
Warnings:					
Information:					
14	NPL Documents	Germano_Unilateral.pdf	3895579	no	8
			fe047ec6ae475028561dbcd02d5ee91090461bd4		
Warnings:					
Information:					
15	NPL Documents	Goetz_MovementDisorder_Process.pdf	5289205	no	7
			ec0d43c85e4d7d7f0aca325b98a8c6ead2765f6		
Warnings:					
Information:					
16	NPL Documents	Goetz_Sarizotan.pdf	5386115	no	8
			7c68faf5743418b59e4b8c5f377aa1a509fce902		

Warnings:					
Information:					
17	NPL Documents	Goetz_MovementDisorder_Scale.pdf	11263322	no	42
			bd3a3566a1c718ba77a7d7b8e5ce8b1d008621cf		
Warnings:					
Information:					
18	NPL Documents	Good_Neuromelanin.pdf	1502116	no	4
			c504bcc38617178eb7a57ebf2d883c853c0442b3		
Warnings:					
Information:					
19	NPL Documents	Huang_Progression.pdf	2018295	no	6
			c9724fb1b7f2944bcf6ff5b8dce406874db11503		
Warnings:					
Information:					
20	NPL Documents	Hauser_Longterm.pdf	6788693	no	9
			a183b416464f544eca2c6b66c1b69e39f7f1e89c		
Warnings:					
Information:					
21	NPL Documents	Hauser_Blood.pdf	2395531	no	5
			513cda56702d8a5699c89db52187ab8ca04c1a1f		
Warnings:					
Information:					
22	NPL Documents	Jenner_Oxidative.pdf	5299501	no	11
			381fa31fdf61140e31c96eb8d79a24a99054bc8a		
Warnings:					
Information:					
23	NPL Documents	Koller_High.pdf	2697577	no	8
			9f4ae9a0208e12b546ca43d6a20a969b103bb0fb		
Warnings:					
Information:					
24	NPL Documents	Kordower_Dopaminergic.pdf	3193845	no	6
			171c593362ada87d90fe0c876bc780d5143c0a5		
Warnings:					
Information:					
25	NPL Documents	Kordower_FetalGrafting.pdf	2775146	no	7
			6fa90dab8fabd92262e2d679f9260edc2a3d0d53		

Warnings:					
Information:					
26	NPL Documents	Kordower_Neuropathologic.pdf	3264799	no	7
			d09c3567b397ab3ef15317dfb4d72170d1ad4510		
Warnings:					
Information:					
27	NPL Documents	KordowerFunctional.pdf	18722970	no	28
			dc0b8054e8fd8c247bde0949326e143bd81cfe6		
Warnings:					
Information:					
28	NPL Documents	Kordower_FetalNigral.pdf	5404713	no	11
			fe21d49eed51cef04b74127b465a19f1ecadccf6		
Warnings:					
Information:					
29	NPL Documents	Kordower_Transplanted.pdf	2050476	no	4
			ab1b32354ac58f90c7e3f85418664c4042ac9bbd		
Warnings:					
Information:					
30	NPL Documents	Kordower_Lewy.pdf	1683337	no	3
			6e0db51274ab28961fd2bef0bf06c18e65ce5d16		
Warnings:					
Information:					
31	NPL Documents	Lieberman_Multicenter.pdf	2777346	no	6
			cea7740b015ba0032f8723d91dc449c0b9289ddb		
Warnings:					
Information:					
32	NPL Documents	Marks_Safety.pdf	6289726	no	9
			f4c5fc559fe6584ba9d8a4d0e6d7b8e84918d8fd		
Warnings:					
Information:					
33	NPL Documents	Martinez_Martin_Prevalence.pdf	4148646	no	7
			e29aba5c9510c61dac1c24a7e5274f3ffa76d1c5		
Warnings:					
Information:					
34	NPL Documents	McNaught_Proteasomal_dysfunction.pdf	6527371	no	13
			3ebe658c5bfa02f261adc98d9673648b8620e8d4		

Warnings:					
Information:					
35	NPL Documents	McNaught_Impairment_ubiquitin.pdf	2922519	no	6
			1c5981032ab3a4ec828ebe1a5c1d130dc830f38a		
Warnings:					
Information:					
36	NPL Documents	McNaught_Proteasomal_Inhibition_nigral.pdf	2363942	no	5
			b4c163a4311195b2dcf4e80e210ec65064a47a57		
Warnings:					
Information:					
37	NPL Documents	McNaught_Systemic_exposure.pdf	6151264	no	14
			24d26e637f34270ca44d4e5a8974d2e03d476df2		
Warnings:					
Information:					
38	NPL Documents	McNaught_Failure_ubiquitin.pdf	4965482	no	6
			9fb42773a752c5da03ed198ce5b8f10655a0f527		
Warnings:					
Information:					
39	NPL Documents	McNaught_Proteasome_Inhibitor-Induced.pdf	2814972	no	5
			2eadc858fb33bfaaa1a8c765ae15defa05421d64		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
40	NPL Documents	Morrison_Program.pdf	21334977	no	16
			64db03b9b854331ded89c1d41226b697f57e795c		
Warnings:					
Information:					
41	NPL Documents	Mytilineou_desmethylselegiline.pdf	1952225	no	3
			f39cd01bb6dc6e9b65dd34f6582c85ea20fd75c		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
42	NPL Documents	Mytilineou_Inhibition.pdf	4416818	no	15
			d36f067bf36bf579dd9da3c2c076faa3855649a4		
Warnings:					

Information:					
43	NPL Documents	Nair_p53Mediates.pdf	7850902	no	11
			494dbbc08ae7cfb433eb4eefde975d64c3a9ebfe		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
44	NPL Documents	Olanaow_Free.pdf	898978	no	2
			968d7003cddaa894989c7a78c80e171dd1ce0d03		
Warnings:					
Information:					
45	NPL Documents	Olanow_Double_blind_Bilateral_fetal.pdf	5620996	no	12
			463fb3424173b015ed486ed65429af5603b5f8e5		
Warnings:					
Information:					
46	NPL Documents	Olanow_Role_Deep_Brain.pdf	3804774	no	7
			5f272cd7987e1e6f43b551ea37ca41f86c418430		
Warnings:					
Information:					
47	NPL Documents	Olanow_ClinicalPattern.pdf	3091194	no	9
			eff1e06cf8b0c2d3d80854965d3f2fd038f79cdd		
Warnings:					
Information:					
48	NPL Documents	Olanow_Fetal_nigral.pdf	3540418	no	8
			407f0334ea831e90fdc089bae6a76ad52d3b4749		
Warnings:					
Information:					
49	NPL Documents	Olanow_OpenMulticenter.pdf	1415223	no	6
			3bcb8796761925e195a90573d361cfe1e9d27a50		
Warnings:					
Information:					
50	NPL Documents	Olanow_Double_Blind_Pergolide_Sinemet.pdf	2021956	no	6
			1dcf1be53b771114481f40faf55f1cac3aaec95e		
Warnings:					
Information:					

51	NPL Documents	Olanow_Double_blind_controlled_treatment.pdf	2112108	no	8
			c3520c15a65514c72c51b093bc160ff751ce4d6c		
Warnings:					
Information:					
52	NPL Documents	Olanow_Multicenter_double_blind.pdf	2935113	no	8
			b34ad4ca71fd7bce2f990e1f6994a7f4faa0795b		
Warnings:					
Information:					
53	NPL Documents	Olanow_Effect_deprenyl.pdf	2373536	no	7
			6d20096851ca436e985d2be8d86ee7b79a35e984		
Warnings:					
Information:					
54	NPL Documents	Olanow_Tolcapone_hepatotoxic.pdf	4077621	no	5
			29cc52aa249fe508bc8660b31bfb6ed7c6a8d2cb		
Warnings:					
Information:					
55	NPL Documents	Olanaow_Tolacpone.pdf	2658130	no	8
			ffa8f6a03c75bf75e4c4b2b25e11b5206f945d3		
Warnings:					
Information:					
56	NPL Documents	Olanow_Double_Blind_Placebo-controlled.pdf	4195678	no	6
			3d9907e012626fe8b84bbcb241e2a0259312f85b		
Warnings:					
Information:					
57	NPL Documents	Olanow_RandomizedDouble.pdf	4488036	no	8
			977a785ed8fbc5dde95b2be893e64e40201872d1		
Warnings:					
The page size in the PDF is too large. The pages should be 8.5 x 11 or A4. If this PDF is submitted, the pages will be resized upon entry into the Image File Wrapper and may affect subsequent processing					
Information:					
58	NPL Documents	Parkinson_Study_Group_Effects_Tocopherol.pdf	3616456	no	8
			963ab81ff2640fae4d86d8b6aa22fddb3b07ea47		
Warnings:					
Information:					
59	NPL Documents	Olanow_Introduction.pdf	3172091	no	8
			d878a2bdf852e57c7d4c73dec36a30ec91c3a08f		

Warnings:					
Information:					
60	Fee Worksheet (PTO-875)	fee-info.pdf	30261	no	2
			ff5903d921192d9c66364f3e7d7ee7974d958b80		
Warnings:					
Information:					
Total Files Size (in bytes):			266176849		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					